[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:essential-thrombocythemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":141,"states":146},"Essential Thrombocythemia",21,18,[8,16,22,29,35,41,48,54,60,67,73,79,85,91,97,103,109,115,121,128,135],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06034002","A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",[12],"Phase 1","RECRUITING","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.650417Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07008118","A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:27.965447Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04644211","Ruxolitinib in Thrombocythemia and Polycythemia Vera",[26],"Phase 2","2026-08-26T02:15:24.145250Z","2026-05-05T02:43:27.955137Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06150157","A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",[12],"2026-08-26T02:16:23.080181Z","2026-04-29T02:57:57.158454Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05025488","Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:29.683710Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06351631","A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",[45],"Phase 3","2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.946262Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-03T03:34:20.548203Z","2026-05-05T02:43:27.444739Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07441694","Study of INCA036978 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.275822Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT05123365","An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",[64],"Phase 1\u002FPhase 2","2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.953012Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06541249","MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial",[26],"2026-08-26T02:16:04.914942Z","2026-04-29T02:57:57.065431Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04282187","Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated\u002FBlast Phase Myeloproliferative Neoplasms",[26],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.738874Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05031897","Two Step Haplo With Radiation Conditioning",[26],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06063486","Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms",[26],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.075022Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06661915","A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)",[26],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.360451Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06523556","Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm\u002FMyelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia",[64],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.949132Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.513961Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06218628","Pacritinib w\u002F Talazoparib in Pts w\u002F Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:35:31.622551Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07362225","MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",[],"2026-08-26T02:15:36.077529Z","2026-05-13T02:55:06.699757Z",{"nct_id":122,"title":123,"phases":124,"status":125,"updated_at":126,"content_modified":127},"NCT07349134","WELL-MPN: A Digital Lifestyle App for Patients With MPNs",[],"NOT_YET_RECRUITING","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.705774Z",{"nct_id":129,"title":130,"phases":131,"status":132,"updated_at":133,"content_modified":134},"NCT06456346","Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)",[45],"ACTIVE_NOT_RECRUITING","2026-08-03T01:58:01.892442Z","2026-05-05T02:43:29.714624Z",{"nct_id":136,"title":137,"phases":138,"status":132,"updated_at":139,"content_modified":140},"NCT06079879","A Study of Bomedemstat (IMG-7289\u002FMK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",[45],"2026-08-03T02:08:28.425355Z","2026-05-05T02:43:26.972656Z",[142],{"biomarker":143,"count":144,"slug":145},"CALR Gene",4,"calr-gene",[147,151,154,158,162,165,168,171,175,178,181,184,187,190,194,197,200,203],{"state":148,"count":149,"slug":150},"California",10,"california",{"state":152,"count":149,"slug":153},"New York","new-york",{"state":155,"count":156,"slug":157},"North Carolina",8,"north-carolina",{"state":159,"count":160,"slug":161},"Florida",6,"florida",{"state":163,"count":160,"slug":164},"Ohio","ohio",{"state":166,"count":160,"slug":167},"Tennessee","tennessee",{"state":169,"count":160,"slug":170},"Texas","texas",{"state":172,"count":173,"slug":174},"Illinois",5,"illinois",{"state":176,"count":173,"slug":177},"Massachusetts","massachusetts",{"state":179,"count":173,"slug":180},"Michigan","michigan",{"state":182,"count":173,"slug":183},"Pennsylvania","pennsylvania",{"state":185,"count":144,"slug":186},"Colorado","colorado",{"state":188,"count":144,"slug":189},"Oregon","oregon",{"state":191,"count":192,"slug":193},"Arizona",3,"arizona",{"state":195,"count":192,"slug":196},"Kansas","kansas",{"state":198,"count":192,"slug":199},"Maryland","maryland",{"state":201,"count":192,"slug":202},"Utah","utah",{"state":204,"count":192,"slug":205},"Virginia","virginia"]